SHARPE
Reported results
- 3Q 2026 net sales (US GAAP): $8,621 thousand, down 12.1% vs. 3Q 2025 net sales of $9,812 thousand
- 3Q 2026 gross profit (US GAAP): $4,840 thousand, down 13.6% vs. 3Q 2025 gross profit of $5,604 thousand
- 3Q 2026 operating income (US GAAP): $2,795 thousand, up 7.0% vs. 3Q 2025 operating income of $2,611 thousand
- 3Q 2026 net income (US GAAP): $2,787 thousand, up 5.9% vs. 3Q 2025 net income of $2,631 thousand
- 3Q 2026 diluted earnings per share (US GAAP): $0.876, up 6.8% vs. 3Q 2025 diluted EPS of $0.820
- 9M 2026 net sales (US GAAP): $25,873 thousand, down 12.2% vs. 9M 2025 net sales of $29,475 thousand
Guidance
- Management’s current year 2026 sales projection, with continued uncertainty, is a total year 2026 consolidated sales decline close to 7%, in contrast to the 12% year-to-date actual decline in 9M 2026 compared to 9M 2025
Notes
The company completed the 15-year amortization of Femcare identifiable assets in 1Q 2026. The Orion Medical Supplies Ltd acquisition was completed at the end of August 2026 for $5,011 thousand including legal fees and stamp duties. The release includes non-GAAP adjusted consolidated EBITDA of $3,735 thousand for 3Q 2026 (43.3% of sales) and $11,303 thousand for 9M 2026 (43.7% of sales).
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-22 (8-K, Item 2.02). Read the original filing on sec.gov.